New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly (NYSE:LLY) announced on Tuesday that its oral weight loss therapy, orforglipron, reached the main goals in a second ...

Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly’s weight loss pill ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

Eli Lilly said it’s moving “with urgency toward global regulatory submissions to potentially meet the needs of patients who ...

(Reuters) -Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of ...

Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant announced positive results from a Phase 3 trial of its oral weight loss pill, paving the way for ...

Eli Lilly's experimental GLP-1 pill, orforglipron, showed promising results in a late-stage trial, aiding weight loss by 10.5 ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...